Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Paul Krogstad Pearl Samson Edward P Acosta Jack Moye Ellen Townley Sarah Bradford Emily Brown Kayla Denson Bobbie Graham Laura Hovind Thucuma Sise Hedy Teppler Sisinyana Ruth Mathiba Lee Fairlie Jana L Winckler Gretchen Slade Tammy Meyers

J Pediatric Infect Dis Soc

Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Published: March 2021

Unlabelled: Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.

Clinical Trials Registration: NCT01751568.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996637	PMC
http://dx.doi.org/10.1093/jpids/piaa039	DOI Listing

Publication Analysis

Top Keywords

aged weeks

living human

human immunodeficiency

immunodeficiency virus

children living

pharmacokinetics safety

safety raltegravir-containing

raltegravir-containing regimen

regimen children

children aged

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!